Vascularization Strategies for Tissue Engineering

Michael Lovett, Ph.D.,¹ Kyongbum Lee, Ph.D.,² Aurelie Edwards, Ph.D.,² and David L. Kaplan, Ph.D.^{1,2}

Tissue engineering is currently limited by the inability to adequately vascularize tissues *in vitro* or *in vivo*. Issues of nutrient perfusion and mass transport limitations, especially oxygen diffusion, restrict construct development to smaller than clinically relevant dimensions and limit the ability for *in vivo* integration. There is much interest in the field as researchers have undertaken a variety of approaches to vascularization, including material functionalization, scaffold design, microfabrication, bioreactor development, endothelial cell seeding, modular assembly, and *in vivo* systems. Efforts to model and measure oxygen diffusion and consumption within these engineered tissues have sought to quantitatively assess and improve these design strategies. This review assesses the current state of the field by outlining the prevailing approaches taken toward producing vascularized tissues and highlighting their strengths and weaknesses.

Introduction

ARGUABLY THE BIGGEST CHALLENGE in the field of tissue engineering remains mass transfer limitations. This is the limiting factor in the size of any tissue construct grown *in vitro*, as well as the subsequent integration of these constructs *in vivo*, regardless of the tissue-specific goal. Within the body, most cells are found no more than 100–200 μm from the nearest capillary, with this spacing providing sufficient diffusion of oxygen, nutrients, and waste products to support and maintain viable tissue.¹ Likewise, when tissues grown in the laboratory are implanted into the body, this diffusion limitation allows only cells within 100–200 μm from the nearest capillary to survive.² Thus, it is critical that a tissue be prevascularized before implantation with proper consideration given to the cell and tissue type, oxygen and nutrient diffusion rates, overall construct size, and integration with host vasculature. In the laboratory, limited diffusion of oxygen is the primary reason that construction of tissues greater than a few hundred microns in thickness is currently not practicable. As most constructs rely on diffusion for oxygen transport into the tissue, gradients are often produced within the constructs, resulting in spatial variations in cell number, viability, and phenotype stemming from differences in oxygen and nutrient concentration.

Current approaches to address this pervasive problem in the field generally fall into six major categories: (a) scaffold functionalization, (b) cell-based techniques, (c) bioreactor designs, (d) microelectromechanical systems (MEMS)-related approaches, (e) modular assembly, and (f) *in vivo* systems (Fig. 1). Scaffolds may be functionalized through different angiogenic factor-loading techniques or through increased

porosity or channeling of scaffolds to form perfusion elements. Examples include vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and heparin-impregnated scaffolds or laser-cored porous scaffolds,^{3–5} with these systems typically aimed at encouraging angiogenesis *in vivo* and reducing oxygen and nutrient gradient formation. Bioreactor systems are designed and employed in the growth of tissues *in vitro* to facilitate improved nutrient and oxygen transport, with examples including perfusion systems, rotating systems, and spinner flasks. These systems result in improved transport and can result in enhanced rate and quality of tissues generated *in vitro*. The use of MEMS and microfluidic technologies to recapitulate the branching network of the microvasculature is an alternative approach being pursued in many labs, with systems generally formed from nondegradable materials such as silicone or polydimethyl siloxane (PDMS), though more recent approaches have focused on developing degradable systems. Cell-based techniques have involved cocultures of endothelial cells with the cell type of interest as well as prevascularization both *in vivo* and *in vitro*. These techniques can provide functional vasculature throughout the construct, though issues of cell culture time and functional anastomosis with host vessels remain a concern. Modular assembly is a newer approach that combines minimal functional units (e.g., an endothelial cell-coated hydrogel or a microtube-hydrogel composite system) to build up a larger vascular network. Finally, *in vivo* systems such as polysurgery techniques or arteriovenous (AV) loops utilize the natural angiogenic potential of an organism to vascularize engineered tissues within the body.

In each case, there are two critical points to producing a viable construct, the ability to measure and model the oxygen

Departments of ¹Biomedical Engineering and ²Chemical and Biological Engineering, Tufts University, Medford, Massachusetts.

FIG. 1. Schematic diagrams of different vascularization approaches. (A) Scaffold functionalization. Tissue engineering scaffolds may be loaded or chemically coupled with angiogenic factors, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and platelet-derived growth factor (PDGF), among others. They may also be designed and engineered to have microchannels or porous microgrooves to improve oxygen/nutrient perfusion or vascular cell alignment, respectively. (B) Cell-based techniques. Multi-cellular spheroid cultures are used to generate capillary-like sprouts when embedded within a biological matrix. Other cell-based techniques include the use of transfected cells to secrete angiogenic factors within a scaffold to induce blood vessel formation. (C) Bioreactor designs. Rotating bioreactors or perfusion bioreactors are used to overcome issues of mass transport in culture, with perfusion bioreactors being particularly useful for forming functional arteries *in vitro*. (D) Microelectromechanical systems-related approaches. Microfluidic systems are used to form a vascular tree-like organization within a synthetic or biodegradable polymer. These systems can subsequently be seeded with endothelial cells to form a rudimentary vasculature. (E) Modular assembly. Microtissues composed of cell-embedded hydrogels covered with a confluent endothelial cell layer have been combined together to form a macrotissue under perfusion, with the endothelial cell layer acting as an antithrombogenic surface. Vessel-embedded hydrogel systems are used to quantitatively measure nutrient and oxygen permeability before translating that knowledge into forming critically sized multi-vascular modules with one inlet and outlet. (F) *In vivo* systems. Confluent cell sheets are stacked and vascularized upon implantation adjacent to arteries and veins before building tissue thickness through the addition of more acellular layers for vascularization. Arteriovenous (AV) loops are used to vascularize tissues *in vivo* within a chamber housing the arteriovenous loop with or without an extracellular matrix (ECM) scaffold or cells. Color images available online at www.liebertonline.com/ten.

tensions throughout the engineered tissue as well as points of functional anastomosis to connect graft-originated pre-vascular structure with host blood vessels. For quantitative measurement of oxygen, consideration of the flow rates through the scaffold, diffusion coefficients within each tissue region, and oxygen consumption rates of each specific cell type dictates the overall model of oxygen distribution within the construct. While each scaffold requires the use of modeling equations specific to its geometric and biological conditions, simple use of Fick's law of diffusion, Michaelis-

Menten kinetics, Navier-Stokes equations, and Darcy's law for flow through porous medium often provide basic understanding of the system. Further direct measurement of oxygen concentrations within the scaffold using oxygen probes or oxygen-sensitive dyes allows these models to be quantitatively evaluated, ultimately providing a more thorough understanding of the vascularization process and the oxygen requirements for a given tissue type. For establishing a connection between prevascularized tissues and host vasculature, consideration for the size of connection, required

flow rates, and ease of integration are critical to the ultimate viability of the implanted tissue. If a tissue-engineered construct is implanted without connection to host blood vessels, oxygen and nutrient supply becomes a diffusion-limited process, resulting in loss of cell viability at the core of the engineered tissue as dictated by its oxygen and nutrient requirements. By designing a prevascularized tissue with connections to host vasculature, the cells within the construct are immediately supplied with the required nutrients from the moment of implantation. Thus, the combination of quantitative measurement and modeling of oxygen and nutrient requirements to account for proper spacing of vessels with connection points for anastomosis to provide immediate functionality *in vivo* serve as the fundamental guide points for the design of vascularized tissues.

In this review, we present the current state of the art for each vascularization technique and the work being performed using each strategy. With particular focus on translating engineered tissues from *in vitro* to *in vivo* studies, the mechanisms of vascularization, quantitative measurements of nutrient and oxygen diffusion, and potential for functional anastomosis with host vasculature will be highlighted for each technique. Further, quantitative methods to model and measure oxygen diffusion and consumption within a tissue will be presented. All together, this review serves to outline the fundamental strategies needed to produce fully vascularized tissues *in vitro* and *in vivo*, with focus on controlling oxygen distribution and vascular integration.

Scaffold Functionalization

Growth factor delivery

One of the classical approaches to producing larger tissues has been to decorate or supplement scaffolds, either natural or synthetic, with pro-angiogenic factors such as VEGF, basic

fibroblast growth factor (bFGF), or PDGF (Table 1).^{6–10} This decoration mimics the *in vivo* condition where these factors are associated with the extracellular matrix (ECM) to stabilize conformation and protect from proteolytic digestion or nonspecific release.³ Single-factor release systems have focused on a broad array of different growth factors, scaffold materials, and means of entrapment. The most basic loading technique is to simply coat or load the scaffold with the growth factor of interest. Loading within a natural biopolymer scaffold is inviting, as they are typically processed in aqueous conditions, are well-characterized, and may be comprised of native ECM molecules. Collagen, in particular, has shown promise with PDGF and has been formed into scaffolds that enhance capillary formation in a dermal wound healing model.^{11,12} Alginate scaffolds loaded with VEGF have also been shown to promote vascularization.¹³ Synthetic scaffolds such as poly(lactic-co-glycolic acid) (PLGA) mixed with VEGF have also supported increased vascularization.^{14,15}

Beyond these basic scaffold-loading approaches, protein modification techniques have been applied to scaffolds by forming binding domains for angiogenic factors via fusion proteins or coupling using 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and *N*-hydroxysuccinimide (NHS) chemistry. Fusion proteins composed of hepatocyte growth factor and a collagen-binding domain have been used to facilitate loading of hepatocyte growth factor, subsequently promoting capillary formation in gel culture *in vitro* as well as blood vessel growth *in vivo*.¹⁶ Likewise, fusion proteins of bFGF and fibrin-binding peptide Kringle1, or PDGF and collagen-binding domains, have been utilized to couple bFGF or PDGF to fibrin or collagen gels, respectively, with each technique producing scaffolds that promoted neovascularization *in vivo* in rat models.^{17,18} As an alternative to modifying the growth factor of interest, scaffolds can

TABLE 1. SUMMARY OF CURRENTLY USED VASCULAR GROWTH/SIGNALING FACTORS

	Growth/signaling factor	Function	Critical issues	References
Time course of delivery	Vascular endothelial growth factor	Most important family of cytokines in neovascularization; initiator of endothelial capillary formation;	Rapidly degraded due to short half-life; excessive amounts cause vascular leakage	3, 6, 7, 14
	Basic fibroblast growth factor	Heparin-binding protein; induces proliferation of ECs, SMCs; initiator of endothelial capillary formation	Rapidly diffuses, requires controlled release; mitogen for wide variety of cell types	3, 18, 26
	Hepatocyte growth factor	Mitogen of hepatocytes and other various cell types; stimulates growth of ECs but not SMCs	Short half-life, rapid diffusion; large amounts of protein required for response	17
	Platelet-derived growth factor	Mitogen for connective tissue cells, released from platelets; recruits SMCs to endothelial linings; promotes vessel maturation	High levels result in vessel destabilization; increased activity linked with several diseases	9, 13, 25
	Angiopoietin-1	Plays key regulatory role in regulating vessel homeostasis; promotes EC migration, stabilization of newly formed capillaries	Overexpression induces endothelial hyperplasia and reduced vessel leakage	3, 8, 10, 11

SMCs, smooth muscle cells; ECs, endothelial cells.

be modified with binding sites. As an example, modification of collagen matrices by covalently incorporating heparin using EDC-NHS chemistry allowed for enhanced immobilization of VEGF via its heparin-binding domain, and the combination of these two angiogenic factors induced increased endothelial cell growth and tube formation.^{19–21} Beyond these methods, others have directly coupled growth factors to scaffolds including VEGF to collagen scaffolds or generated a gene-activated matrix by coating plasmid coding for human VEGF onto collagen sponges.^{22,23}

While success has been realized with these different types of bulk-loading and surface-coupling approaches, there remain problems with restricting the delivery of these pro-angiogenic factors to the region of need as well as controlling the temporal release profile.³ Thus, drug-loaded microspheres incorporated into scaffolds have been explored, either with or without bulk or surface loading as described above. As an example, the release kinetics of two growth factors, VEGF and PDGF, were studied together in a polymer system (PLGA) where VEGF was mixed with the PLGA particles used to produce the scaffold and PDGF was pre-encapsulated into microspheres before forming the scaffold. This procedure deposited the VEGF largely on the surface of the polymer where it was rapidly released. The polymer-encapsulated PDGF, however, was more evenly distributed throughout the scaffold and was released more slowly through bulk degradation.²⁴ As a result, upon implantation *in vivo*, the mechanism of dual delivery allowed larger, more mature blood vessels to be formed as opposed to smaller, incomplete vessels formed using a single factor delivery technique.²⁴ Synthetic microsphere encapsulation has also been used to trap bFGF in PLGA, incorporating these microspheres into alginate scaffolds or simply injecting them with small intestinal submucosa and preadipocytes, both of which have been shown to significantly enhance vascularization.^{25,26} In terms of biodegradable microspheres, chitosan–gelatin microspheres containing bFGF have been developed and incorporated into a porous chitosan–gelatin scaffold, demonstrating initial fast release kinetics over 2 days before achieving a steady release profile lasting 2 weeks, displaying promise for vascularization.²⁷

Ultimately, the ability to direct the timing and release of growth factors will control the degree of vascularization within the tissue.²⁸ To direct angiogenesis, it is critical to determine the release kinetics of the angiogenic factors from the scaffold. The time course of vascularization may not be

compatible with maintaining cell viability throughout the construct; that is, cells at the center of the tissue undergo apoptosis before vascularization is complete. Because of this dependence on cell response (i.e., endothelial cell migration, proliferation, and organization into capillary-like structures) to vascularize the scaffold, these techniques are not highly controllable and do not directly consider the mass transfer requirements (i.e., oxygen and nutrients) of the cell-seeded scaffold (Table 2). Thus, these techniques may be more effectively employed as a means of enhancing vascularization in the context of quantitative scaffold design, where cellular metabolism and cell density are accounted for and gradients of vascular factors may be established through their controlled release, ultimately driving the development of the required vasculature. Further, cues from native vasculogenesis and angiogenesis may be applied to scaffold design, presenting a physiologically relevant time course of release. In natural vasculogenesis, differentiation and formation of angioblasts into primitive blood vessels is induced by VEGF receptor activation, with concentration gradients and maintenance of threshold levels required for differentiation and angiogenesis.²⁹ Sprouting of new vessels through angiogenesis is then induced by angiopoietins, ligands for the endothelial cell receptor kinase TIE, which modulates VEGF activity and may direct angiogenesis through the pattern of signaling by VEGF and TIE receptors (TIE-1 and TIE-2).³⁰ Immature vessels are stabilized by recruiting vascular smooth muscle cells (SMCs) and pericytes as well as generating ECM, with this maturation and remodeling process regulated largely by PDGF and transforming growth factor- β 1, with perfusion, shear stress, and oxygenation playing critical roles, ultimately rendering the endothelial cells independent of VEGF.^{31,32} Further branching and remodeling is controlled by matrix metalloproteinase activity, influencing cell migration and differentiation through the release of pro-angiogenic factors within the matrix.³¹ Scaffold design should apply this knowledge of the temporal expression profiles of these cytokines during vessel development *in vivo* to form biomaterial scaffolds loaded with these factors, specifically with control over release rates over time and thus vascular development.

Scaffold design and engineering

In addition to loading scaffolds with angiogenic factors and controlling release profiles, the scaffolds themselves may be engineered to promote vascularization. Through scaffold

TABLE 2. SCAFFOLD FUNCTIONALIZATION TECHNIQUES FOR VASCULAR TISSUE ENGINEERING

	Growth factor delivery	Scaffold design/engineering
Mechanism of vascularization	Recruitment of vascular cells via angiogenic factor release	Channels and alignment to promote perfusion and cellular organization
Tissues and cell types cocultured	Wound healing; bone, adipose, and dermal tissue; fibroblasts	Cardiac tissue; fibroblasts
Quantitative measurement of nutrient and oxygen diffusion	Very limited $\rightarrow$ laser Doppler to measure perfusion <i>in vivo</i>	Ultrasound imaging, O ₂ distribution with microelectrodes, modeling O ₂ gradients, nutrient diffusion chamber
Points of functional anastomosis	None, only vascular cell recruitment	None reported, but could be designed
References	3, 6, 12–28	5, 33–44

design and engineering, issues of oxygen gradients and flow regimes, as well as cell alignment and angiogenesis, may be controlled (Table 2). In the field of tissue engineering, the ability to maintain suitable oxygen tensions and nutrient diffusion throughout the scaffold is critical for cell viability and function. One of the ways that this has been addressed is through the use of channeled scaffolds. Channeled scaffolds have been formed by incorporating phosphate-based glass fibers into collagen scaffolds or by using a laser cutting system to bore holes into a scaffold.^{5,33} By incorporating phosphate-based glass fibers into collagen scaffolds, channel size and distribution is controllable based on the original size of the glass fibers (10–50 μm) and the fiber-to-fiber spacing. Thus, when these fibers are degraded, microchannels are left behind that offer potential for flow and improved cell viability.³³ In a more tissue-specific approach, channeled scaffolds formed using a laser cutting system addressed previously observed issues of cell viability in constructs of rat neonatal myocytes seeded on collagen sponge scaffolds.³⁴ In previous studies, a linear decrease in oxygen concentration was observed from the surface of the construct to the bottom, correlating with a decrease in cell viability. Cell viability was approximately 60% within 500 μm of the surface, but quickly dropped to 5–15% at depths greater than 1000 μm .³⁴ To address this issue, an elastomeric scaffold [poly(glycerol-sebacate)] was developed with a parallel array of channels (370 μm in diameter, 410 μm spacing) aimed at mimicking the capillary network and allowed for flow of culture medium throughout the construct. This approach, combined with addition of perfluorocarbons in the medium as oxygen carriers, produced significantly improved cardiac tissues based on total cell number, expression of markers of cardiac differentiation, and excitation thresholds.⁵

Besides microchanneling, directing scaffold vascularization through micro-patterning or molecular gradients has been explored, offering scaffold cues that can effectively dictate the migration and alignment of cells within the construct. Work with scaffold patterning has included the formation of grooved, porous poly-caprolactone scaffolds. These scaffolds were produced by mixing the poly-caprolactone with PLGA micro/nanoparticles and casting the polymer onto a grooved surface before leaching out the micro/nanospheres. This process produces surfaces that are conducive for vascular cell alignment and also increase medium diffusion.³⁵ By stacking these layers, it may be possible to build up three-dimensional (3D) tissues with cellular organization for blood vessel formation, an outcome that may also be directed by forming gradients within the scaffold. Previous gradient work has largely focused on migration of vascular cells in response to concentration or surface-density gradients of growth factors such as VEGF, bFGF, arginine-glycine-aspartic acid (RGD)-peptide or fibronectin.^{36–39} While these studies have largely focused on surface gradients, gradients within 3D scaffolds are also being pursued. In a recent study, collagen–hyaluronic acid (HA) scaffolds were produced by mixing varying concentrations of HA, an inhibitor of angiogenesis, into collagen gels with the goal of controlling vascular sprout rate and direction. By implanting endothelial cell spheroids into these gels and monitoring the number, direction, and length of capillary-like sprouts, directionality and enhanced sprouting rates away from the HA gradient were found.⁴⁰ These techniques, combined with

previously described techniques for enhancing migration, offer powerful tools to control vascularization for tissue engineering.

Future scaffold designs may be improved through the use of an emerging tool, computer-aided tissue engineering, which can help model and design scaffolds with controlled internal and external architecture, particularly vascular channel elements of different sizes and shapes.^{41,42} Using tissue and/or scaffold imaging (computed tomography, magnetic resonance imaging, and optical microscopy) to generate computer-aided designed tissue or scaffold models, tissue engineering scaffolds can be built to match native features of porosity, mechanical strength, and vascularization, with the correct spatial positioning and morphology.^{41,42} Through these techniques a vascularized modular 3D scaffold may be developed with tight control over the vascular tree, vessel dimensions, and interconnectivity.^{41,43} Controlled spatial deposition of different biopolymers, growth factors, and cells may also be achieved as multi-nozzle systems have been developed.⁴⁴ Overall, these scaffolding techniques offer fine control over vascularization potential and offer a multitude of options in scaffold design and engineering to create functional tissue outcomes.

Cell-Based Techniques

Endothelial cell cocultures

To help compensate for issues with growth factor delivery, cocultures with endothelial cells have been utilized to provide a starting point for vascularization; however, consideration for quantity of cells/vessels required for a particular tissue is critical.^{45,46} These techniques have been used for *in vitro* vascularization of a variety of tissues, including bone and adipose, with the endothelial cells introduced into the tissues via 3D multicellular spheroids or simple mixing of cultures.^{45,47} Endothelial cell spheroids produce capillary-like sprouts, especially in the presence of angiogenic factors such as VEGF and bFGF, or in coculture with fibroblasts, but sprout diameter and length was reduced in cocultures of endothelial cells and osteoblasts.^{45,46,48} In the case of fibroblasts, it has been shown that fibroblasts modulate endothelial cell network formation, suggesting the critical need for complex mixed spheroid cocultures to adequately mimic *in vivo* angiogenesis.⁴⁹ Despite the successes achieved using these spheroid models, issues of functional anastomosis into host vasculature remain. For bone tissue engineering, endothelial cell and osteoprogenitor cell (human mesenchymal stem cells [hMSCs]) spheroid cocultures formed a pre-vascular network *in vitro* but, upon implantation *in vivo*, displayed no functional perfusion.⁵⁰

Beyond spheroid cultures, simple cocultures of endothelial cells, fibroblasts, and other cell types have been used to grow vascularized skin, skeletal muscle, and bone tissues, among others.^{51–53} Through simple cocultures of different tissue-specific cell types in a biopolymer gel such as collagen or on porous polymer scaffolds, spontaneous formation of tubular structures was observed with expression of typical markers of microvasculature (Table 3).^{54–67} In several cases, the role of fibroblasts was critical for the formation and the maintenance of the microvasculature as they were associated with neosynthesis of ECM as well as increasing levels of VEGF.^{51,52} Another cell type, neural progenitor cells, has also shown the

TABLE 3. VASCULAR CELL MARKERS AT DIFFERENT STAGES OF DIFFERENTIATION

Endothelial cell markers					
Early/differentiation		Constitutive phenotype		Activated phenotype	
Marker	Function	Marker	Function	Marker	Function
CD34	Hematopoietic precursor marker	PECAM-1 (CD31)	Platelet/endothelial cell adhesion molecule-1; role in leukocyte recruitment, migration	VCAM-1 (CD106)	Vascular cell adhesion molecule-1; upregulated by inflammatory cytokines
PECAM-1 (CD31)	Surface adhesion molecule	eNOS	Endothelial nitric oxide synthase; production of NO, regulation of vascular function	ICAM-1 (CD54)	Intercellular adhesion molecule-1; upregulated by inflammatory cytokines
VE-cadherin	Surface marker; cell-cell junctions	Factor VIII	Clotting factor in thrombotic pathway	E-selectin (CD62E)	Inflammation-induced adhesion molecule
		VE-cadherin	Cell-cell junctions, demonstrates confluent endothelium	P-selectin (CD62P)	Cytokine-activated adhesion molecule
		vWF	von Willebrand factor, clotting protein		
SMC markers					
Early/differentiation		Synthetic phenotype		Contractile phenotype	
Marker	Function	Marker	Function	Marker	Function
SM α -actin	Contractile protein of SMCs; first marker of differentiated SMCs	↓ SM α -actin	Contractile protein of SMCs	↑ SM α -actin	Contractile protein of SMCs
Calponin	Potential regulator of SM contraction	↓ Calponin	Potential regulator of SM contraction	↑ Calponin	Potential regulator of SM contraction
SM-22- α	Calponin-related cytoskeletal protein SMC-specific marker	↑ SMemb/ NMHC-B	Embryonic/nonmuscle isoform of myosin heavy chain	↑ SM-MHC	Smooth muscle myosin heavy chain essential component of contractile system
Caldesmon	Protein that binds calmodulin, actin, myosin	↓ Caldesmon	Binds Ca ²⁺ -calmodulin, actin, myosin; mediates Ca ²⁺ -dependent SM contraction inhibition	↑ Caldesmon	Binds calmodulin, actin, myosin; mediates Ca ²⁺ -dependent SM contraction inhibition
Tropomyosin	Rod-like proteins in tight association with action	↓ Tropomyosin	Binds to actin grooves; mediates Ca ²⁺ -dependent regulation of actin–myosin interaction	↑ Tropomyosin	Binds to actin grooves; mediates Ca ²⁺ -dependent regulation of actin–myosin interaction
				Elastin	Extracellular matrix protein; source of vessal compliace

References [49–62]

PECAM-1, platelet/endothelial cell adhesion molecule-1; VE-cadherin, vascular endothelial cadherin; eNOS, endothelial nitric oxide synthase; vWF, von Willebrand factor; VCAM-1, vascular cell adhesion molecule-1; ICAM-1, intercellular adhesion molecule-1; SM, smooth muscle; NMHC-B, non-muscle myosin heavy chain-B; MHC, myosin heavy chain.

ability to enhance tubular formation both *in vitro* and in forming a functional microcirculation *in vivo*.⁶⁸ Together, these results underlie the complexity of cell–cell signaling, cytokine release, and growth factor delivery in forming a functional microvasculature. Combining layers of endothelial cells and layers of other cells, such as fibroblasts, within native hydrogels has been pursued. By spacing a layer of dermal fibroblasts at a distance 1.8–4.5 mm from human umbilical vein endothelial cell-coated beads within a fibrin gel fed with media containing VEGF and bFGF, endothelial cells produced capillaries based on the distance of the endothelial cells from the fibroblasts.⁶⁹ This approach could help dictate the formation of a vascular network in an engineered tissue *in vitro*, although without control over number and spacing of vessels or means of functional anastomosis to blood vessels *in vivo* (Table 4).

Growth factor-producing cells

An additional cell-based approach that has become a focus of vascular research is the transfection of cells to overexpress angiogenic factors. These cells can be seeded within biomaterial scaffolds and release cytokines that modulate vascular cell migration, proliferation, and maturation into tubular vessels in a more controlled, biomimetic manner than simple scaffold loading (Table 4). In a study aimed at producing tissue engineered bone, combinations of scaffolds were coated with or without VEGF-plasmid DNA and loaded with hMSCs transfected with or without the VEGF plasmid.⁷⁰ Compared to controls, VEGF plasmid-coated scaffolds and VEGF-transfected cells demonstrated significantly enhanced vascularization, osteogenesis, and scaffold resorption compared to control groups, with the VEGF-transfected cells producing the highest rate of vascularization.⁷⁰ Similarly, rat MSCs transfected with VEGF before injecting the transfected cells into the infarct zones of an ischemic rat heart model was studied to stimulate revascularization.⁷¹ Compared to control injections of nontransfected cells, plasmid alone, and media, the hearts injected with the VEGF-transfected cells displayed the greatest reduction in infarct size, best heart function, and the greatest capillary density.⁷¹ In addition to these transfection-based approaches, recent results using MSCs derived from human peripheral blood indicate that these cells secrete VEGF and induce vascularization in a mouse skin defect model.⁷² As opposed to growth factor scaffold-loading-based techniques, these cell-based approaches demonstrate significant potential for sustained growth factor release over time and better overall vascularization.

Bioreactor Designs

Rotating bioreactors

In generating tissues *in vitro*, bioreactor systems are often used to perfuse culture medium through a porous scaffold to try to maintain cell viability in the middle and homogeneity throughout the construct.⁷³ While these efforts generally improve outcomes, these improvements do not solve problems of heterogeneity in tissue outcomes due to fluid flow along paths of least resistance. More significantly, these approaches do not address the transition and integration of the tissue grown *in vitro* to an *in vivo* setting. Specifically, these tissue constructs do not develop a functional vasculature that offers points of anastomosis to host vessels *in vivo* (Table 5).

Work using rotating bioreactors has been primarily confined to endothelial cell culture on microcarrier beads using a horizontal rotating bioreactor originally developed by NASA.^{74,75} The horizontally rotating bioreactors, or slow-turning lateral vessels, were designed as a rotating cylinder of culture medium, with a gas-permeable membrane for oxygen and carbon dioxide exchange, and fittings for sampling or medium exchange.^{75,76} The speed of the rotation could be controlled to match the settling velocity of the tissue constructs, keeping them suspended within the vessel. This approach has been used for engineering of bone, cartilage, and cardiac tissue.^{76–79} In terms of vascularized tissue engineering, early events (growth and differentiation) of ocular angiogenesis have been studied in these bioreactors, using human retinal cells and bovine endothelial cells in coculture on microcarrier beads and grown in the horizontally rotating bioreactors for up to 5 weeks. In coculture, the endothelial cells formed cords and capillary-like structures as well as the beginning of sprouts, indicators of a developing vasculature.⁷⁵

Perfusion bioreactors

In addition to rotating vessels, a wide variety of perfusion bioreactors have been developed to address issues of oxygen and nutrient transport throughout tissue engineered scaffolds. These devices have been used in the culture of several tissue types, including bone, adipose, and cardiac, among others.^{73,80–82} While these studies support a variety of designs and tissue types, they still lack a vascular component (Table 5). Vascular perfusion bioreactors typically focus on producing a tissue-engineered blood vessel, not on vascularizing another tissue type. Using pulsatile conditions typically found *in vivo*, functional arteries may be grown *in vitro*

TABLE 4. CELL-BASED TECHNIQUES FOR VASCULAR TISSUE ENGINEERING

	Endothelial cell cocultures	Growth factor-producing cells
Mechanism of vascularization	Use of endothelial cells to form capillary-like structures	Transfected cells used to modulate angiogenic growth factor delivery
Tissues and cell types cocultured	Skin, bone, adipose, and muscle tissue; fibroblasts, neural progenitor cells	Bone, myocardial, and dermal tissue
Quantitative measurement of nutrient and oxygen diffusion	Luciferase or other fluorescence-based imaging, fiber optic oxygen sensors	None reported
Points of functional anastomosis	None, requires ingrowth of host vessels	None, only vascular cell recruitment
References	45–53, 68, 69	70–72

TABLE 5. BIOREACTOR DESIGNS FOR VASCULAR TISSUE ENGINEERING

	<i>Rotating bioreactors</i>	<i>Perfusion bioreactors</i>
Mechanism of vascularization	More efficient distribution of culture medium throughout construct	Mimic flow of vessels <i>in vivo</i> to improve vascular cell viability and function
Tissues and cell types cocultured	Bone, cartilage, and cardiac tissue; retinal and mesenchymal stem cells	Bone and cardiac tissue, small arteries; mesenchymal stem cells, SMCs, cardiomyocytes
Quantitative measurement of nutrient and oxygen diffusion	Limited → dye-protein permeability, bulk media metabolism analysis	Limited → dye tracers of perfusion, media metabolism analysis, modeling
Points of functional anastomosis	None, requires ingrowth of host vessels	Yes, for arteries grown <i>in vitro</i>
References	74–79	73, 80–88

using different polymers (synthetic [polyglycolic acid, polyester] or natural [collagen, fibrin, silk]) and different cell-seeding techniques (static or perfusion; SMCs, endothelial cells, or both).^{83–87} Only recently have vessels been used as a means of perfusing a larger tissue, such as the abdominal aorta of a rat as a core perfusion element within an artificial myocardial matrix of collagen and neonatal rat cardiomyocytes.⁸⁸ The perfused tissues displayed enhanced cell viability and increased metabolic activity when compared to nonperfused controls.⁸⁸ This approach has additional promise in that it provides points for functional anastomosis at each end of the vessel, offering translation from *in vitro* culture to an *in vivo* setting.

MEMS-Related Approaches

Microfluidic design from synthetic polymers

Microfabrication techniques have gained popularity as they offer fine control over the formation of a microvascular network. Through the fabrication of a negative mold, a complex capillary pattern may be formed and serve as a template for molding materials.⁸⁹ These capillary networks may be perfused and endothelialized, providing a mimic of natural vasculature as well as oxygen and nutrient delivery and waste removal (Table 6). Standard techniques use plasma etching or lithographic techniques to produce desired features with micron-scale precision, with replica molds of PDMS cast from the negative feature molds. These molds may then be bonded with one another before seeding with endothelial cells to form cylindrical capillary channels.⁸⁹ Direct-write assembly has been used to form 3D microfluidic

devices for vascular tissue engineering.⁹⁰ Recently, more biomimetic techniques have emerged to develop vascular networks that are representative of *in vivo* conditions. Computational modeling has been used to understand flow behavior for microfluidic systems based on physiological data.⁹¹ Direct-write laser technology has been utilized to form multiple-depth channel systems with diameter changes between parent and daughter vessels that mimic physiological systems.⁹² In addition, techniques to deliver and measure oxygen content within a microvascular network could have broader implications in tissue engineering as a quantitative means of assessing vascular spacing.⁹³

Despite all of these advances, because these systems are typically formed from nondegradable materials such as PDMS, they offer limited use *in vivo* due to issues of biofouling, nondegradability, and limited integration to surrounding tissues. Further, limited integration with host vasculature is an issue, with surgical removal required at prescribed time frames, compounding the challenge of repair and function. As a result, more recent approaches have focused on degradable microfluidic systems to address these issues.

Biodegradable microfluidics

To address issues of biocompatibility that are typically observed with synthetic, nondegradable materials such as PDMS or silicone, biocompatible and biodegradable materials for microfluidic applications are being pursued.⁹⁴ Elastomers such as poly(glycerol sebacate) (PGS) that are biocompatible and biodegradable have been explored for

TABLE 6. MICROELECTROMECHANICAL SYSTEMS-RELATED APPROACHES TO VASCULAR TISSUE ENGINEERING

	<i>Synthetic polymer microfluidics</i>	<i>Biodegradable microfluidics</i>
Mechanism of vascularization	Micromolding to replicate vascular tree, seed with endothelial cells	Micromolding capillary network using biodegradable substrates (vascular tree)
Tissues and cell types cocultured	Hepatic tissue	Endothelial cells, hepatocytes, chondrocytes
Quantitative measurement of nutrient and oxygen diffusion	Dye mixing/diffusion, flow/pressure experiments, oxygen sensitive dyes, computational modeling	Fluorescent dye perfusion/diffusion, diffusion and transport rate modeling
Points of functional anastomosis	None, poor <i>in vivo</i> integration	None reported, but could be designed
References	89–93	94–96, 98–100

vascular tissue engineering.^{94,95} Devices are produced using similar techniques as synthetic microfluidics, with PGS layers formed by casting onto negative molds, released using a sacrificial layer, and bonded together by physically adhering and curing the films under vacuum. By subsequently stacking single-layer microfluidic networks, with consideration for oxygen limitations, 3D scaffolds with complex vascular microchannels can be produced for different tissue types.⁹⁵ Similar techniques have been applied to forming microvascular networks from a natural protein biopolymer, silk fibroin.⁹⁶ Silk is a biocompatible and biodegradable protein derived from cocoons of the *Bombyx mori* silkworm and can be processed under aqueous conditions, be chemically functionalized, and promote cellular adhesion. Silk is also a mechanically robust material with slow, controllable degradation, making it a useful material for microfabrication for tissue-based applications.^{96,97} By casting silk onto negative molds, treating with methanol to form micromolded water-stable films, and binding to a flat layer using aqueous silk solution, microfluidic devices composed entirely of silk protein are produced. These devices have demonstrated improved mechanical properties compared to PGS films and also support hepatocyte culture, making these a promising option for degradable microfluidics.⁹⁶

In addition to stacking different layers of biodegradable materials, other approaches to building 3D vascularized constructs have focused on creating microfluidic networks within cell-seeded hydrogels, including alginate, collagen, and fibrin. Using calcium alginate as a scaffold, a lithographic process was used to form microfluidic hydrogel networks seeded with chondrocytes.⁹⁸ Channels of 100 μm in diameter were formed within the gel, and the diffusion of fluorescent molecules, cell viability within the gel, and microchannel spacing were characterized to maintain a uniform metabolic environment throughout the bulk of the scaffold. In addition, two independent networks were incorporated into the hydrogel, maintaining steady-state gradients throughout the gel for both reactive and nonreactive solutes. These characterizations with respect to fluorescein, rhodamine, and calcein-acetoxymethyl ester (AM) were all done quantitatively, calculating values for the diffusion coefficients of the fluorescent molecules, rates of cell metabolism, and the Krogh length for characteristic variations in concentrations, among others.⁹⁸ Similar lithographic techniques have been used to micropattern collagen gels, using a sacrificial digestion of patterned Matrigel embedded within the gel to produce micron-sized cavities.⁹⁹ Using a slightly different approach, gelatin meshes were used to form a capil-

lary network, micromolding the meshes in microfluidic networks before embedding within a collagen or fibrin hydrogel, melting and flushing the hydrogel, and perfusing with macromolecules and particles of interest.¹⁰⁰ Channels 50 μm in width were produced and could be seeded with endothelial cells to form an endothelialized network within a fibroblast-seeded hydrogel, a rudimentary vascularized tissue. As with the alginate work, transport within these capillary networks was quantitatively characterized in terms of diffusion rates under different flow conditions using fluorescent molecules.¹⁰⁰ By coupling quantitative modeling and comparative analysis between expected and experimental results, it is possible to generate microfluidic networks for specific tissue types (Table 6). This approach serves as a critical point in the future of tissue vascularization.

Modular Assembly

Endothelial cell-coated modules

An emerging technique for producing prevascularized tissues involves the modular assembly of endothelialized microtissues to form a macro-tissue. These microtissues may be generated through gravity-enforced self-assembly of primary cells or via seeding of collagen gels with a desired cell type.^{101–103} The microtissue modules are then coated with endothelial cells before combining in a mold or large tube to form a macro-tissue. These packed-bed macro-tissues can be perfused with medium or whole blood, or be connected to host vasculature through the use of a chicken chorioallantoic membrane assay.^{101–103} This technique has been used to generate tissues using hepatocytes, chondrocytes, and SMCs. The critical endothelial cell component on the module surface is what allows for functional perfusion by acting as an antithrombogenic surface, delaying clotting times, and inhibiting loss of platelets.^{102,104} However, while these modular tissues demonstrate the ability to be perfused as well as integrate with host vasculature over time, they do not replicate the tree-like vasculature exhibited *in vivo* and do not facilitate tissue integration *in vivo* by providing components that enable immediate anastomosis to host vasculature (Table 7).

Vessel-embedded hydrogels

Another developing modular approach is the perfusion of single- or multi-channel hydrogels. These systems are promising given that they can address two of the underlying issues with vascularization, measurement of oxygen/nutrient

TABLE 7. MODULAR ASSEMBLY APPROACHES TO VASCULAR TISSUE ENGINEERING

	Endothelial cell-coated modules	Vessel-embedded hydrogels
Mechanism of vascularization	Perfusion of packed bed of endothelial cell-coated microtissues	Perfusion of single- or multi-channel hydrogels
Tissues and cell types cocultured	Hepatocytes, chondrocytes, SMCs	Perivascular cells, SMCs, mesenchymal stem cells
Quantitative measurement of nutrient and oxygen diffusion	Limited $\rightarrow$ modeling flow profiles and porosity	Fluorescent dye perfusion/diffusion, diffusion and transport rate modeling
Points of functional anastomosis	None, requires ingrowth of host vessels	Yes, for one inlet/outlet designs
References	101–104	105–107

TABLE 8. *IN VIVO* APPROACHES TO VASCULAR TISSUE ENGINEERING

	Polysurgery techniques	Arteriovenous loops
Mechanism of vascularization	Cell sheet engineering with intervals of surgery to continue vascularization <i>in vivo</i>	Angiogenesis from arteriovenous shunt within chamber <i>in vivo</i>
Tissues and cell types cocultured	Cardiac, cornea, trachea, epithelial	Cardiac, bone, skeletal muscle, skin
Quantitative measurement of nutrient and oxygen diffusion	None reported	Hypoxia staining, angiography in large models
Points of functional anastomosis	Yes, for cell sheets vascularized directly over an existing host artery and/or vein	Yes, vein or synthetic graft forms the shunt loop
References	108–110	111–119

diffusion, and connection with host vasculature (Table 7). Work on perfused vascular tubes embedded within collagen gels has produced vessels that display characteristics of native venules and capillaries, including barrier function, resistance to leukocyte adhesion, and inflammatory stimulus response.¹⁰⁵ These microvessels were produced by embedding a 120- μ m-diameter needle within a collagen gel, removing it, and seeding with endothelial cells. Upon maturation of the vessel, barrier function and leukocyte adhesion was assessed under perfusion, including quantitative evaluation of tube permeability in the absence or presence of histamine or thrombin, two inflammatory agonists, using fluorescently labeled bovine serum albumin or dextran.¹⁰⁵ These studies provide fundamental insight into vascular development and perfusion, serving as potential building blocks for more complex studies, including the perfusion of multiple microvessels. By seeding SMCs onto strands of nylon line within a perfusion chamber, a parallel array of microvessels was formed that could be connected to a perfusion system.¹⁰⁶ The SMCs on the lines proliferated over a 21-day culture, at which time the perfusion chamber was filled with agar, the nylon was removed, and the microvessels were perfused. The ability of multiple microvessels to be perfused using one inlet and outlet suggests that functional anastomosis may be achieved *in vivo* with slight modification of the system. Combinations of these approaches involving perfusion bioreactors and multiple microvessels may represent the most straightforward and productive approach to *in vitro* tissue vascularization.

Recent efforts have focused on bridging the gap between quantitative modeling of diffusion for proper vessel spacing and functional anastomosis for *in vivo* applications using silk microtube-hydrogel composite systems for vascular applications.¹⁰⁷ Using hMSCs and human umbilical vein endothelial cells as the primary cell types, cell viability and differentiation as a function of distance from a single silk microtube in a perfused or statically cultured system can be studied. These results, in combination with oxygen and nutrient diffusion modeling and measurement, would dictate the critical spacing of microtube vessels and the overall dimensions of minimally sized modular elements. These tissues would be built from these minimal functional units, connected with one another to form one inlet and one outlet of perfusion and serve as sites of integration into host vasculature. This approach could address the major limiting factors in the field of prevascularization, providing a framework for building larger, more complex tissues.

In Vivo Systems

Polysurgery techniques

Beyond efforts to build vascularized tissues *in vitro*, researchers have used cell sheet engineering and polysurgery techniques to produce tissues up to 1 mm in thickness (Table 8). Cell sheet engineering techniques have been used in corneal surface reconstruction, blood vessel grafts, and myocardial tissue engineering, among others.^{58,108,109} To form vascularized myocardium, confluent sheets of neonatal rat cardiomyocytes were grown and stacked to form tissues up to $\sim 80\mu$ m in thickness, the limit for this particular cell and tissue type.¹¹⁰ To overcome this limitation, the layered cell sheets were transplanted into rats and allowed to vascularize over a period of 1–3 days. Upon complete vascularization of the transplant, another cell sheet was added and vascularized, continuing in this layer-by-layer transplantation approach until a ~ 1 -mm-thick myocardium was achieved. Further, by directly transplanting the cell sheets over an existing host artery and vein, points of anastomosis were incorporated into the growing tissue to serve as points of connection when transplanting the engineered tissue from one host to another.¹¹⁰ As with the *in vitro* systems with one inlet and outlet aimed at translating to *in vivo* implantation, this system provides the critical vascular blood flow to supply the cells with the oxygen, nutrients, and waste removal that impart immediate functionality to the tissue upon connection of the prevascular structure to the host blood vessels.

AV loops

Another *in vivo* system that utilizes host blood vessels to develop prevascular structures is the culture of scaffolds within AV loop chambers. In this intrinsic vascularization model, a vein or synthetic graft is used to form a shunt loop between an artery and a vein and is enclosed within a chamber that is either empty or housing an ECM scaffold to be vascularized.^{111–113} Using an empty AV loop in a rat model, constructs formed extensive arteriole-capillary-venule networks within a fibrin matrix exuded from the AV loop, with initial development occurring between 7 and 10 days and maturing over time. This maturation occurred with a concurrent decrease in hypoxia staining, which was prevalent during the 7–10 days, but decreased over time and was absent from the 28 day time point onward.¹¹¹ Similar models have been used to incorporate ECM scaffolds such as

collagen–glycosaminoglycan within the AV loop chamber by embedding the AV loop within two scaffolds and suturing to secure the loop. As in the empty chamber model, extensive new tissue growth and vascularization was observed, though alterations in the scaffold pore size and biochemical loading may further improve, direct, and control neoangiogenesis within the AV loop.¹¹⁴ Additional complexity may also be incorporated into the AV loop by adding cells to the scaffold before implantation. By mixing neonatal rat cardiomyocytes in Matrigel before incorporating the matrix within the AV loop culture chamber, spontaneously contracting constructs were developed that demonstrate organized assembly, are highly vascularized, and approach thicknesses of approximately 2 mm.¹¹⁵ In general, this approach represents a significant step forward in vascularization of tissues and has been applied in a variety of tissue types including cardiac, bone, and skeletal muscle tissue (Table 8).^{116,117} Further, work beyond the small animal model of the rat and into larger animal models such as sheep, afford the ability to monitor vascularization in real-time using angiography techniques and complex 3D reconstructions demonstrating the power of this model system.¹¹⁸ Despite these successes, however, the rapid vascularization necessary for adequate cellular oxygen supply upon implantation is still lacking, but could be improved through prevascularization *in vitro* before implantation or biochemically modifying scaffolds to stimulate angiogenesis and cell proliferation *in situ*.¹¹⁹ These methods, combined with improved imaging techniques for monitoring angiogenesis and oxygen tensions *in vivo*, could ultimately provide the time course for clinically relevant vascularization of engineered tissues.

Oxygen Modeling, Measurement, and Integration in Vascularized Tissues

Modeling of oxygen transport

Beyond the techniques for vascularization, there is a clear need for detailed modeling of oxygen distribution in an engineered tissue construct. *In vivo*, oxygen and nutrients are supplied over physiological distances by the vasculature, with local transport dictated by intracapillary resistance, vascular permeability, interstitial flow, and cell metabolism.^{120,121} Capillary hematocrit, diffusion through the en-

dothelium, physicochemical properties of the diffusing molecules, composition of the ECM, and rates of consumption all have critical effects on oxygen and nutrient transport. Thus, accurate modeling of engineered tissues *in vitro* should consider these issues as well.^{122,123}

In considering oxygen transport, the most basic modeling components to be described are fluid flow, oxygen diffusion, and oxygen consumption. Within a cultivated tissue, the inflow of oxygen may be supplied by diffusion or a vascular element as described above (e.g., silk tube and channeled scaffold). Previous efforts to model oxygen gradients in vascular systems have largely focused on one-dimensional (1D), steady-state transport.

For tissues cultivated under static (non-agitated batch culture) conditions, the supply of oxygen is dictated by its effective diffusivity (Fig. 2A). These tissues are typically modeled using Fick's law:

$$J_t = -D_t \frac{\partial C_{O_2}^t}{\partial x} \quad (1)$$

where J_t is the diffusive flux in the tissue [mol/(m²·s)], D_t is the diffusion coefficient of oxygen in the tissue [m²/s], $C_{O_2}^t$ is the tissue oxygen concentration [mol/m³], and x is the distance [m] into the tissue from the vascular element (or other source of oxygen).^{124,125} To determine the oxygen distribution within a cell-seeded construct, a consumption term needs to be specified to account for the rate of oxygen consumption of the growing cells. This consumption term is typically expressed assuming Michaelis-Menten kinetics:

$$q = \frac{q_{\max} C_{O_2}^t}{K_m + C_{O_2}^t} \quad (2)$$

where q is the rate of oxygen consumption per cell [mol/(cell·s)], $q_{\max}$ is the maximum rate of oxygen consumption per cell [mol/(cell·s)], and K_m is the Michaelis-Menten constant [μ M]. If the value of K_m (0.01–6.9 μ M for multiple cell types)^{125–127} is much smaller than the average oxygen concentrations in the vasculature (130 and 54 μ M in arterial and venous blood, respectively),¹²⁷ the reaction rate can be assumed to be zero order:¹²⁸

$$q = q_{\max} \quad (3)$$

FIG. 2. Basic geometries for modeling oxygen diffusion and consumption. (A) Static cell-seeded scaffold or hydrogel with uni-axial diffusion of oxygen. Oxygen diffusion is characterized by Fick's Law with oxygen gradients within the scaffold at steady state controlled by the concentration of cells and their corresponding metabolic rate, described by Michaelis-Menten kinetics. (B) Perfused cell-seeded scaffold or hydrogel with diffusion of oxygen from multiple boundaries. Oxygen diffusion and consumption may be described using Fick's Law and Michaelis-Menten kinetics, respectively, with the flow of media described by the Navier-Stokes equations. These more complex geometries require careful consideration of boundary conditions, diffusion coefficients, and metabolic rates to accurately model oxygen gradients within the engineered tissue. Color images available online at www.liebertonline.com/ten.

The volumetric rate of oxygen consumption (Q) [mol/(m³·s)] is obtained by multiplying q by the concentration of cells (C_{cell}) [cells/m³]:

$$Q = C_{cell} \cdot q \quad (4)$$

The steady-state distribution of O₂ throughout the construct is then determined by solving the oxygen conservation equation:

$$D_t \frac{\partial^2 C_{O_2}^t}{\partial x^2} - Q = 0 \quad (5)$$

with appropriate boundary conditions. In general, a homogeneous distribution of cells is assumed. If the oxygen consumption rate is also taken to be constant (Equation 3), an analytical solution can be derived. These basic equations can be applied to a variety of engineered tissues, including several different scaffold geometries (films, hydrogels, porous sponges, and composites) provided that the oxygen gradient is 1D and oxygen consumption is isotropic.

In tissues supplied by a flow of medium, oxygen convection and diffusion in the perfusing fluid must be taken into consideration (Fig. 2B). In the case of a capillary perfusing an engineered tissue, the Navier-Stokes equations may be used to describe the flow of an incompressible fluid.¹²⁸ If the flow is taken to be steady, laminar, 1D, and fully developed, the equation for capillary flow in the z -direction simplifies to

$$\frac{\partial P}{\partial z} = \mu \left[\frac{1}{r} \frac{\partial}{\partial r} \left(r \frac{\partial v_z}{\partial r} \right) \right] \quad (6)$$

where z is the axial direction, r is the radial direction, P is the pressure [Pa], μ is the viscosity [Pa·s], and v_z is the axial velocity [m/s]. The conservation equation for oxygen in the perfusing capillary can be written as:

$$v_z(r) \frac{\partial C_{O_2}^c}{\partial z} = D_c \left[\frac{1}{r} \frac{\partial}{\partial r} \left(r \frac{\partial C_{O_2}^c}{\partial r} \right) + \frac{\partial^2 C_{O_2}^c}{\partial z^2} \right] \quad (7)$$

where $C_{O_2}^c$ and D_c are, respectively, the concentration and diffusion coefficient of oxygen in the capillary. Following specification of the boundary conditions, the flow velocity is computed first, and the oxygen concentration profiles in the perfusing capillary and the surrounding tissue are subsequently determined. Such a two-dimensional, steady-state analysis of a construct usually requires numerical computations, and models may be developed and solved using multi-physics modeling software such as FemLab (Comsol, Burlington, MA).

While these equations include the basic terms needed to model oxygen transport in tissue engineering, they are certainly not comprehensive. Within composite scaffolds, regions may need to be distinguished using different material properties or modeling equations, such as Darcy's Law for flow through a porous medium. Modeling of transient phenomena may also be performed to determine changes in oxygen gradients over time, necessitating that time derivatives be added to the equations described above. Other specific cases may require modeling the kinetics of oxygen dissociation from carriers, intracapillary resistance, vascular permeability, and pressure gradients.^{121,129} Nevertheless, the general equations and methods described above provide a

basic framework for modeling oxygen distribution within 3D tissue constructs.

Methods of oxygen measurement

To accurately model oxygen transport, several techniques have been applied to measure the spatial distribution of oxygen within tissues. Gross measurements of oxygen in the bulk media within a bioreactor, or sampling at the inlet and outlet, have been performed using a blood-gas analyzer.^{76,130} While this method provides information on the pH, oxygen, and carbon dioxide levels, at an accuracy of 2% for oxygen partial pressures, it does not provide information on oxygen tension within the construct. To partially address this issue, oxygen-sensitive dyes have been developed and incorporated into oxygen-sensing foils or microplates, either directly within a tissue matrix or as part of an oxygen microsensor probe. By incorporating an oxygen-sensitive dye into the foil or plate, phosphorescent intensity readings may be recorded and converted into oxygen tensions, ultimately yielding estimates of cellular oxygen consumption rates.¹³¹ Tissue samples or engineered constructs may be grown on these plates, and changes in the oxygen concentration in the tissue can be measured over weeks of culture.¹³² These systems, however, only measure oxygen concentration within one region of a construct and do not provide sufficient spatial sensitivity to measure differences in oxygen tensions as a function of depth without physical cross-sectioning of the samples before measurement.

To address this issue, oxygen microelectrodes have been developed to offer fine spatial resolution of oxygen measurements directly within a scaffold or tissue. These systems use gold-plated platinum wires, or glass optical fibers with a fluorescent probe at the end, to measure oxygen tension.¹³³ For a platinum wire electrode, the probe is introduced into a substrate, the oxygen reacts with the cathode, and the resultant differences in the current flow are related back to oxygen tension based on two-point calibration using, for example, an air-saturated medium and an anoxic solution.^{34,133,134} In the case of a fluorescence-based probe, a pulsed blue light-emitting diode light is used to excite the sensor probe at the tip of the optical fiber. In the presence of oxygen, some of the excess energy is transferred to the oxygen molecule, quenching the fluorescence signal, with the decrease in fluorescence directly proportional to the oxygen tension in the sample.¹³⁵ The microelectrodes have diameters as small as 5 μ m and, when used with a micromanipulator, offer spatial resolution on the order of 10 μ m.¹³⁴ These measurements may be performed in media, collagen hydrogels, polymer scaffolds, or tissue explants, under either static or flow conditions.^{34,125,134,136} Thus, these systems offer a wide variety of applications within tissue engineering, offering high levels of sensitivity and specificity. Despite this versatility, these probes are not suitable for all applications, particularly those involving more robust scaffolds where probes are subject to breaking due to their small size. In addition, the invasive nature of inserting a probe into a scaffold to measure oxygen tension may compromise scaffold integrity and sterility, necessitating a noninvasive method for measuring oxygen concentrations.

To measure oxygen tensions noninvasively, porphyrin-based oxygen-sensitive dyes used to prepare oxygen-

sensitive foils have been prepared within aqueous media, injected in blood *in vivo*, or mixed directly within a tissue matrix.^{137–139} In each case, oxygen quenches the phosphorescence of albumin-bound porphyrins in a concentration-dependent manner, and the decay of the phosphorescent signal can be related back to oxygen tension (P_{O_2}) using the Stern-Volmer equation^{131,140}:

$$\tau_o/\tau = 1 + k_q\tau_o(P_{O_2}) \quad (8)$$

where τ is the time constant of decay, τ_o is the time constant of decay in absence of oxygen, and k_q is a quenching constant; both constants τ_o and k_q are obtained by system calibration.¹⁴¹ Using this method, oxygen measurements can be achieved noninvasively. This method has previously been applied to characterize the *in vivo* oxygen tension within the vasculature or interstitial space of healthy and diseased mice.^{140,142,143} In terms of *in vitro* work, these phosphorescent dyes have been incorporated within collagen and alginate gels, seeded with chondrocytes, and cultured over a 24-h period, with oxygen distributions characterized both spatially and temporally.¹³⁹ Porphyrin-based dyes have also been applied within microfluidic devices with tree-like vasculature to determine mass transfer characteristics.⁹³ Future work should focus on bridging the gap between *in vitro* and *in vivo* measurements, with longer-term cultures *in vitro* and full characterization of the oxygen transport properties to ensure the maintenance of viable tissue *in vivo*.

Integration of oxygen delivery and modeling in vascularized tissues

In each of the preceding strategies for vascularizing engineered tissues, the role of oxygen delivery is critical for the survival of the cultured cells. However, this may be achieved not with vascularization, but with simple perfusion. In fact, in using some of the previously examined techniques, perfusion without any vascular cells was sufficient to supply oxygen throughout a scaffold. This applies in particular to channeled scaffolds and some of the microfluidic systems, demonstrating that perfusion can take place in a scaffold with no vessels as long as the scaffolds are highly porous and/or have low cell densities. This minimizes the distance of oxygen diffusion into the tissue as well as the volumetric rate of oxygen consumption, providing adequate oxygen supply for all cells within the scaffold. For scaffolds with low porosity or high cell density, however, these parameters are vastly increased, limiting the diffusion of oxygen to portions of the scaffold. By incorporating vascular cells into the engineered tissue, functional vessels may be formed, reducing capillary spacing and increasing the rate of oxygen supply throughout the construct. In addition, the development of these vessels provides connection points between the pre-vascularized tissue and host blood vessels, a critical point for translating a quantitatively designed perfused construct *in vitro* to a fully vascularized tissue *in vivo*.

Conclusions and Future Directions

The ability to vascularize tissues *in vitro* is currently a main focus within the field of tissue engineering. As perfusion and oxygen transport have direct effects on cell viability and differentiation, researchers are currently limited to tissues only a

few millimeters in thickness. These limitations are imposed by mass transfer and are defined by the balance between the metabolic demand of the cellular components in the system and the size of the scaffold. As a result, reducing the distance for oxygen diffusion can only be addressed through perfusion and/or the development of a functional vasculature. Current approaches include growth factor delivery, channeled scaffolds, perfusion bioreactors, microfluidics, cell cocultures, cell functionalization, modular assembly, and *in vivo* systems. As discussed above, while these approaches may improve cell viability or generate capillary-like structures within a tissue construct, there is still a fundamental disconnect between defining the metabolic needs of a tissue through quantitative measurements of oxygen and nutrient diffusion and the potential ease of integration into host vasculature for future *in vivo* implantation. Thus, a combinatorial strategy to address the challenges of mass transport is needed to optimize *in vitro* approaches related to *in vivo* success in terms of oxygen and nutrient supply as well as connection with host blood vessels. The need to combine engineering design of scaffolds for implantation and modeling of mass transfer with relevant experimental data to build this foundation remains pervasive in the field, though quantitative techniques using biodegradable microfluidics and modular approaches are beginning to be more common.

Based on the above challenges and needs, we suggest that future work continue the development of the modularized approach to tissue engineering, where scaffold and tissue size, transport issues, and surgical implantation *in vivo* are considered from the outset. Using a quantitative approach to transport and design, minimally sized units could be derived from oxygen transport data and modeling, providing a basis for required capillary spacing on a tissue-specific basis. In addition, by targeting minimally sized units with the ability to be coupled with one another to generate larger systems, the ability for anastomosis with host vasculature *in vivo* would be maintained. Cues from previous work with growth factor delivery, directed scaffold assembly, and microfluidic coupling should also be considered and incorporated in these systems, but all with the ultimate design goals of quantitative assessment and functional anastomosis in mind. Importantly, this approach represents a generic strategy that can be employed by any laboratory, where specific variables (cell density, metabolic rate, etc.) can be imported into the design to determine minimally sized units for any cell type, biomaterial matrix, or target tissue.

Acknowledgments

We would like to acknowledge funding from the Tissue Engineering Resource Center through the National Institutes of Health (NIH) grant EB002520 from the National Institute of Biomedical Imaging and Bioengineering.

Disclosure Statement

No competing financial interests exist.

References

1. Jain, R.K., Au, P., Tam, J., Duda, D.G., and Fukumura, D. Engineering vascularized tissue. *Nat Biotechnol* **23**, 821, 2005.

2. Rouwkema, J., Rivron, N.C., and van Blitterswijk, C.A. Vascularization in tissue engineering. *Trends Biotechnol* **26**, 434, 2008.
3. Zisch, A.H., Lutolf, M.P., and Hubbell, J.A. Biopolymeric delivery matrices for angiogenic growth factors. *Cardiovasc Pathol* **12**, 295, 2003.
4. Zhang, G., and Suggs, L.J. Matrices and scaffolds for drug delivery in vascular tissue engineering. *Adv Drug Deliv Rev* **59**, 360, 2007.
5. Radisic, M., Park, H., Chen, F., Salazar-Lazzaro, J.E., Wang, Y., Dennis, R., Langer, R., Freed, L.E., and Vunjak-Novakovic, G. Biomimetic approach to cardiac tissue engineering: oxygen carriers and channeled scaffolds. *Tissue Eng* **12**, 2077, 2006.
6. Zisch, A.H., Lutolf, M.P., Ehrbar, M., Raeber, G.P., Rizzi, S.C., Davies, N., Schmokel, H., Bezuidenhout, D., Djonov, V., Zilla, P., and Hubbell, J.A. Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. *FASEB J* **17**, 2260, 2003.
7. Bauer, S.M., Bauer, R.J., Liu, Z.J., Chen, H., Goldstein, L., and Velazquez, O.C. Vascular endothelial growth factor-C promotes vasculogenesis, angiogenesis, and collagen constriction in three-dimensional collagen gels. *J Vasc Surg* **41**, 699, 2005.
8. Fiedler, U., and Augustin, H.G. Angiopoietins: a link between angiogenesis and inflammation. *Trends Immunol* **27**, 552, 2006.
9. Andrae, J., Gallini, R., and Betsholtz, C. Role of platelet-derived growth factors in physiology and medicine. *Genes Dev* **22**, 1276, 2008.
10. Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T.N., Yancopoulos, G.D., and McDonald, D.M. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. *Science* **286**, 2511, 1999.
11. Friess, W. Collagen—biomaterial for drug delivery. *Eur J Pharm Biopharm* **45**, 113, 1998.
12. Royce, P.M., Kato, T., Ohsaki, K., and Miura, A. The enhancement of cellular infiltration and vascularisation of a collagenous dermal implant in the rat by platelet-derived growth factor BB. *J Dermatol Sci* **10**, 42, 1995.
13. Elcin, Y.M., Dixit, V., and Gitnick, G. Extensive *in vivo* angiogenesis following controlled release of human vascular endothelial cell growth factor: implications for tissue engineering and wound healing. *Artif Organs* **25**, 558, 2001.
14. Huang, Y.C., Kaigler, D., Rice, K.G., Krebsbach, P.H., and Mooney, D.J. Combined angiogenic and osteogenic factor delivery enhances bone marrow stromal cell-driven bone regeneration. *J Bone Miner Res* **20**, 848, 2005.
15. Kaigler, D., Wang, Z., Horger, K., Mooney, D.J., and Krebsbach, P.H. VEGF scaffolds enhance angiogenesis and bone regeneration in irradiated osseous defects. *J Bone Miner Res* **21**, 735, 2006.
16. Kitajima, T., Terai, H., and Ito, Y. A fusion protein of hepatocyte growth factor for immobilization to collagen. *Biomaterials* **28**, 1989, 2007.
17. Zhao, W., Han, Q., Lin, H., Gao, Y., Sun, W., Zhao, Y., Wang, B., Chen, B., Xiao, Z., and Dai, J. Improved neovascularization and wound repair by targeting human basic fibroblast growth factor (bFGF) to fibrin. *J Mol Med* **86**, 1127, 2008.
18. Lin, H., Chen, B., Sun, W., Zhao, W., Zhao, Y., and Dai, J. The effect of collagen-targeting platelet-derived growth factor on cellularization and vascularization of collagen scaffolds. *Biomaterials* **27**, 5708, 2006.
19. Steffens, G.C., Yao, C., Prevel, P., Markowicz, M., Schenck, P., Noah, E.M., and Pallua, N. Modulation of angiogenic potential of collagen matrices by covalent incorporation of heparin and loading with vascular endothelial growth factor. *Tissue Eng* **10**, 1502, 2004.
20. Yao, C., Prevel, P., Koch, S., Schenck, P., Noah, E.M., Pallua, N., and Steffens, G. Modification of collagen matrices for enhancing angiogenesis. *Cells Tissues Organs* **178**, 189, 2004.
21. Markowicz, M., Heitland, A., Steffens, G.C., and Pallua, N. Effects of modified collagen matrices on human umbilical vein endothelial cells. *Int J Artif Organs* **28**, 1251, 2005.
22. Shen, Y.H., Shoichet, M.S., and Radisic, M. Vascular endothelial growth factor immobilized in collagen scaffold promotes penetration and proliferation of endothelial cells. *Acta Biomater* **4**, 477, 2008.
23. Geiger, F., Bertram, H., Berger, I., Lorenz, H., Wall, O., Eckhardt, C., Simank, H.G., and Richter, W. Vascular endothelial growth factor gene-activated matrix (VEGF165-GAM) enhances osteogenesis and angiogenesis in large segmental bone defects. *J Bone Miner Res* **20**, 2028, 2005.
24. Richardson, T.P., Peters, M.C., Ennett, A.B., and Mooney, D.J. Polymeric system for dual growth factor delivery. *Nat Biotechnol* **19**, 1029, 2001.
25. Perets, A., Baruch, Y., Weisbuch, F., Shoshany, G., Neufeld, G., and Cohen, S. Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres. *J Biomed Mater Res A* **65**, 489, 2003.
26. Marra, K.G., Defail, A.J., Clavijo-Alvarez, J.A., Badylak, S.F., Taieb, A., Schipper, B., Bennett, J., and Rubin, J.P. FGF-2 enhances vascularization for adipose tissue engineering. *Plast Reconstr Surg* **121**, 1153, 2008.
27. Liu, H., Fan, H., Cui, Y., Chen, Y., Yao, K., and Goh, J.C. Effects of the controlled-released basic fibroblast growth factor from chitosan-gelatin microspheres on human fibroblasts cultured on a chitosan-gelatin scaffold. *Biomacromolecules* **8**, 1446, 2007.
28. Mikos, A.G., Herring, S.W., Ochareon, P., Elisseeff, J., Lu, H.H., Kandel, R., Schoen, F.J., Toner, M., Mooney, D., Atala, A., Dyke, M.E., Kaplan, D., and Vunjak-Novakovic, G. Engineering complex tissues. *Tissue Eng* **12**, 3307, 2006.
29. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. *FASEB J* **13**, 9, 1999.
30. Risau, W. Mechanisms of angiogenesis. *Nature* **386**, 671, 1997.
31. Jain, R.K. Molecular regulation of vessel maturation. *Nat Med* **9**, 685, 2003.
32. Carmeliet, P. Manipulating angiogenesis in medicine. *J Intern Med* **255**, 538, 2004.
33. Nazhat, S.N., Neel, E.A., Kidane, A., Ahmed, I., Hope, C., Kershaw, M., Lee, P.D., Stride, E., Saffari, N., Knowles, J.C., and Brown, R.A. Controlled microchannelling in dense collagen scaffolds by soluble phosphate glass fibers. *Biomacromolecules* **8**, 543, 2007.
34. Radisic, M., Malda, J., Epping, E., Geng, W., Langer, R., and Vunjak-Novakovic, G. Oxygen gradients correlate with cell density and cell viability in engineered cardiac tissue. *Biotechnol Bioeng* **93**, 332, 2006.
35. Sarkar, S., Lee, G.Y., Wong, J.Y., and Desai, T.A. Development and characterization of a porous micro-patterned scaffold for vascular tissue engineering applications. *Biomaterials* **27**, 4775, 2006.

36. Liu, L., Ratner, B.D., Sage, E.H., and Jiang, S. Endothelial cell migration on surface-density gradients of fibronectin, VEGF, or both proteins. *Langmuir* **23**, 11168, 2007.
37. DeLong, S.A., Moon, J.J., and West, J.L. Covalently immobilized gradients of bFGF on hydrogel scaffolds for directed cell migration. *Biomaterials* **26**, 3227, 2005.
38. Burdick, J.A., Khademhosseini, A., and Langer, R. Fabrication of gradient hydrogels using a microfluidics/photopolymerization process. *Langmuir* **20**, 5153, 2004.
39. Smith, J.T., Elkin, J.T., and Reichert, W.M. Directed cell migration on fibronectin gradients: effect of gradient slope. *Exp Cell Res* **312**, 2424, 2006.
40. Borselli, C., Oliviero, O., Battista, S., Ambrosio, L., and Netti, P.A. Induction of directional sprouting angiogenesis by matrix gradients. *J Biomed Mater Res A* **80**, 297, 2007.
41. Nam, J., Starly, B., Darling, A., and Sun, W. Computer aided tissue engineering for modeling and design of novel tissue scaffolds. *Comput Aided Des Appl* **1**, 633, 2004.
42. Sun, W., Darling, A., Starly, B., and Nam, J. Computer-aided tissue engineering: overview, scope and challenges. *Biotechnol Appl Biochem* **39**, 29, 2004.
43. Li, J., Regli, W.C., and Sun, W. An approach to integrating shape and biomedical attributes in vascular models. *CAD Comput Aided Des* **39**, 598, 2007.
44. Khalil, S., Nam, J., and Sun, W. Multi-nozzle deposition for construction of 3D biopolymer tissue scaffolds. *Rapid Prototyping J* **11**, 9, 2005.
45. Wenger, A., Stahl, A., Weber, H., Finkenzeller, G., Augustin, H.G., Stark, G.B., and Kneser, U. Modulation of *in vitro* angiogenesis in a three-dimensional spheroidal coculture model for bone tissue engineering. *Tissue Eng* **10**, 1536, 2004.
46. Wenger, A., Kowalewski, N., Stahl, A., Mehlhorn, A.T., Schmal, H., Stark, G.B., and Finkenzeller, G. Development and characterization of a spheroidal coculture model of endothelial cells and fibroblasts for improving angiogenesis in tissue engineering. *Cells Tissues Organs* **181**, 80, 2005.
47. Borges, J., Mueller, M.C., Padron, N.T., Tegtmeier, F., Lang, E.M., and Stark, G.B. Engineered adipose tissue supplied by functional microvessels. *Tissue Eng* **9**, 1263, 2003.
48. Finkenzeller, G., Torio-Padron, N., Momeni, A., Mehlhorn, A.T., and Stark, G.B. *In vitro* angiogenesis properties of endothelial progenitor cells: a promising tool for vascularization of *ex vivo* engineered tissues. *Tissue Eng* **13**, 1413, 2007.
49. Kunz-Schughart, L.A., Schroeder, J.A., Wondrak, M., van Rey, F., Lehle, K., Hofstaedter, F., and Wheatley, D.N. Potential of fibroblasts to regulate the formation of three-dimensional vessel-like structures from endothelial cells *in vitro*. *Am J Physiol Cell Physiol* **290**, C1385, 2006.
50. Rouwkema, J., de Boer, J., and Van Blitterswijk, C.A. Endothelial cells assemble into a 3-dimensional prevascular network in a bone tissue engineering construct. *Tissue Eng* **12**, 2685, 2006.
51. Black, A.F., Berthod, F., L'Heureux, N., Germain, L., and Auger, F.A. *In vitro* reconstruction of a human capillary-like network in a tissue-engineered skin equivalent. *FASEB J* **12**, 1331, 1998.
52. Levenberg, S., Rouwkema, J., Macdonald, M., Garfein, E.S., Kohane, D.S., Darland, D.C., Marini, R., Van Blitterswijk, C.A., Mulligan, R.C., D'Amore, P.A., and Langer, R. Engineering vascularized skeletal muscle tissue. *Nat Biotechnol* **23**, 879, 2005.
53. Unger, R.E., Sartoris, A., Peters, K., Motta, A., Migliaresi, C., Kunkel, M., Bulnheim, U., Rychly, J., and James Kirkpatrick, C. Tissue-like self-assembly in cocultures of endothelial cells and osteoblasts and the formation of microcapillary-like structures on three-dimensional porous biomaterials. *Biomaterials* **28**, 3965, 2007.
54. Fraser, S.T., Ogawa, M., Nishikawa, S., and Nishikawa, S. Embryonic stem cell differentiation as a model to study hematopoietic and endothelial cell development. *Methods Mol Biol* **185**, 71, 2002.
55. Newman, P.J. The biology of PECAM-1. *J Clin Invest* **100**, S25, 1997.
56. Newman, P.J., and Newman, D.K. Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology. *Arterioscler Thromb Vasc Biol* **23**, 953, 2003.
57. Kader, K.N., Akella, R., Ziats, N.P., Lakey, L.A., Harasaki, H., Ranieri, J.P., and Bellamkonda, R.V. eNOS-overexpressing endothelial cells inhibit platelet aggregation and smooth muscle cell proliferation *in vitro*. *Tissue Eng* **6**, 241, 2000.
58. L'Heureux, N., Paquet, S., Labbe, R., Germain, L., and Auger, F.A. A completely biological tissue-engineered human blood vessel. *FASEB J* **12**, 47, 1998.
59. Garlanda, C., and Dejana, E. Heterogeneity of endothelial cells: specific markers. *Arterioscler Thromb Vasc Biol* **17**, 1193, 1997.
60. Augustin, H.G., Kozian, D.H., and Johnson, R.C. Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. *BioEssays* **16**, 901, 1994.
61. Szmitko, P.E., Wang, C.H., Weisel, R.D., De Almeida, J.R., Anderson, T.J., and Verma, S. New markers of inflammation and endothelial cell activation part I. *Circulation* **108**, 1917, 2003.
62. Owens, G.K. Regulation of differentiation of vascular smooth muscle cells. *Physiol Rev* **75**, 487, 1995.
63. Owens, G.K., Kumar, M.S., and Wamhoff, B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. *Physiol Rev* **84**, 767, 2004.
64. Kumar, M.S., and Owens, G.K. Combinatorial control of smooth muscle-specific gene expression. *Arterioscler Thromb Vasc Biol* **23**, 737, 2003.
65. Feil, S., Hofmann, F., and Feil, R. SM22alpha modulates vascular smooth muscle cell phenotype during atherogenesis. *Circ Res* **94**, 863, 2004.
66. Shanahan, C.M., and Weissberg, P.L. Smooth muscle cell heterogeneity: patterns of gene expression in vascular smooth muscle cells *in vitro* and *in vivo*. *Arterioscler Thromb Vasc Biol* **18**, 333, 1998.
67. Sobue, K., Hayashi, K., and Nishida, W. Expressional regulation of smooth muscle cell-specific genes in association with phenotypic modulation. *Mol Cell Biochem* **190**, 105, 1999.
68. Ford, M.C., Bertram, J.P., Hynes, S.R., Michaud, M., Li, Q., Young, M., Segal, S.S., Madri, J.A., and Lavik, E.B. A macroporous hydrogel for the coculture of neural progenitor and endothelial cells to form functional vascular networks *in vivo*. *Proc Natl Acad Sci USA* **103**, 2512, 2006.
69. Griffith, C.K., Miller, C., Sainson, R.C., Calvert, J.W., Jeon, N.L., Hughes, C.C., and George, S.C. Diffusion limits of an *in vitro* thick prevascularized tissue. *Tissue Eng* **11**, 257, 2005.
70. Geiger, F., Lorenz, H., Xu, W., Szalay, K., Kasten, P., Claes, L., Augat, P., and Richter, W. VEGF producing bone marrow stromal cells (BMSC) enhance vascularization and

- resorption of a natural coral bone substitute. *Bone* **41**, 516, 2007.
71. Yang, J., Zhou, W., Zheng, W., Ma, Y., Lin, L., Tang, T., Liu, J., Yu, J., Zhou, X., and Hu, J. Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. *Cardiology* **107**, 17, 2007.
 72. Egana, J.T., Fierro, F.A., Kruger, S., Bornhauser, M., Huss, R., Lavandero, S., and Machens, H.G. Use of human mesenchymal cells to improve vascularization in a mouse model for scaffold-based dermal regeneration. *Tissue Eng Part A* **15**, 1191, 2008.
 73. Cartmell, S.H., Porter, B.D., Garcia, A.J., and Guldberg, R.E. Effects of medium perfusion rate on cell-seeded three-dimensional bone constructs *in vitro*. *Tissue Eng* **9**, 1197, 2003.
 74. Sanford, G.L., Ellerson, D., Melhado-Gardner, C., Sroufe, A.E., and Harris-Hooker, S. Three-dimensional growth of endothelial cells in the microgravity-based rotating wall vessel bioreactor. *In Vitro Cell Dev Biol Anim* **38**, 493, 2002.
 75. Dutt, K., Sanford, G., Harris-Hooker, S., Brako, L., Kumar, R., Sroufe, A., and Melhado, C. Three-dimensional model of angiogenesis: coculture of human retinal cells with bovine aortic endothelial cells in the NASA bioreactor. *Tissue Eng* **9**, 893, 2003.
 76. Obradovic, B., Carrier, R.L., Vunjak-Novakovic, G., and Freed, L.E. Gas exchange is essential for bioreactor cultivation of tissue engineered cartilage. *Biotechnol Bioeng* **63**, 197, 1999.
 77. Marolt, D., Augst, A., Freed, L.E., Vepari, C., Fajardo, R., Patel, N., Gray, M., Farley, M., Kaplan, D., and Vunjak-Novakovic, G. Bone and cartilage tissue constructs grown using human bone marrow stromal cells, silk scaffolds and rotating bioreactors. *Biomaterials* **27**, 6138, 2006.
 78. Augst, A., Marolt, D., Freed, L.E., Vepari, C., Meinel, L., Farley, M., Fajardo, R., Patel, N., Gray, M., Kaplan, D.L., and Vunjak-Novakovic, G. Effects of chondrogenic and osteogenic regulatory factors on composite constructs grown using human mesenchymal stem cells, silk scaffolds and bioreactors. *J Royal Soc Interface* **5**, 929, 2008.
 79. Bursac, N., Papadaki, M., White, J.A., Eisenberg, S.R., Vunjak-Novakovic, G., and Freed, L.E. Cultivation in rotating bioreactors promotes maintenance of cardiac myocyte electrophysiology and molecular properties. *Tissue Eng* **9**, 1243, 2003.
 80. Grayson, W.L., Bhumiratana, S., Cannizzaro, C., Chao, P.H., Lennon, D.P., Caplan, A.I., and Vunjak-Novakovic, G. Effects of initial seeding density and fluid perfusion rate on formation of tissue-engineered bone. *Tissue Eng Part A* **14**, 1809, 2008.
 81. Zhao, F., and Ma, T. Perfusion bioreactor system for human mesenchymal stem cell tissue engineering: dynamic cell seeding and construct development. *Biotechnol Bioeng* **91**, 482, 2005.
 82. Radisic, M., Yang, L., Boublik, J., Cohen, R.J., Langer, R., Freed, L.E., and Vunjak-Novakovic, G. Medium perfusion enables engineering of compact and contractile cardiac tissue. *Am J Physiol Heart Circ Physiol* **286**, H507, 2004.
 83. Niklason, L.E., Gao, J., Abbott, W.M., Hirschi, K.K., Houser, S., Marini, R., and Langer, R. Functional arteries grown *in vitro*. *Science* **284**, 489, 1999.
 84. Baguneid, M., Murray, D., Salacinski, H.J., Fuller, B., Hamilton, G., Walker, M., and Seifalian, A.M. Shear-stress preconditioning and tissue-engineering-based paradigms for generating arterial substitutes. *Biotechnol Appl Biochem* **39**, 151, 2004.
 85. Isenberg, B.C., Williams, C., and Tranquillo, R.T. Endothelialization and flow conditioning of fibrin-based media-equivalents. *Ann Biomed Eng* **34**, 971, 2006.
 86. Williams, C., and Wick, T.M. Perfusion bioreactor for small diameter tissue-engineered arteries. *Tissue Eng* **10**, 930, 2004.
 87. Williams, C., and Wick, T.M. Endothelial cell-smooth muscle cell co-culture in a perfusion bioreactor system. *Ann Biomed Eng* **33**, 920, 2005.
 88. Kofidis, T., Lenz, A., Boublik, J., Akhyari, P., Wachsmann, B., Mueller-Stahl, K., Hofmann, M., and Haverich, A. Pulsatile perfusion and cardiomyocyte viability in a solid three-dimensional matrix. *Biomaterials* **24**, 5009, 2003.
 89. Borenstein, J.T., Terai, H., King, K.R., Weinberg, E.J., Kaazempur-Mofrad, M.R., and Vacanti, J.P. Microfabrication technology for vascularized tissue engineering. *Biomed Microdevices* **4**, 167, 2002.
 90. Theriault, D., White, S.R., and Lewis, J.A. Chaotic mixing in three-dimensional microvascular networks fabricated by direct-write assembly. *Nat Mater* **2**, 265, 2003.
 91. Carraro, A., Hsu, W.M., Kulig, K.M., Cheung, W.S., Miller, M.L., Weinberg, E.J., Swart, E.F., Kaazempur-Mofrad, M., Borenstein, J.T., Vacanti, J.P., and Neville, C. *In vitro* analysis of a hepatic device with intrinsic microvascular-based channels. *Biomed Microdevices* **10**, 795, 2008.
 92. Lim, D., Kamotani, Y., Cho, B., Mazumder, J., and Takayama, S. Fabrication of microfluidic mixers and artificial vasculatures using a high-brightness diode-pumped Nd:YAG laser direct write method. *Lab Chip* **3**, 318, 2003.
 93. Vollmer, A.P., Probst, R.F., Gilbert, R., and Thorsen, T. Development of an integrated microfluidic platform for dynamic oxygen sensing and delivery in a flowing medium. *Lab Chip* **5**, 1059, 2005.
 94. Fidkowski, C., Kaazempur-Mofrad, M.R., Borenstein, J., Vacanti, J.P., Langer, R., and Wang, Y. Endothelialized microvasculature based on a biodegradable elastomer. *Tissue Eng* **11**, 302, 2005.
 95. Bettinger, C.J., Weinberg, E.J., Kulig, K.M., Vacanti, J.P., Wang, Y.D., Borenstein, J.T., and Langer, R. Three-dimensional microfluidic tissue-engineering scaffolds using a flexible biodegradable polymer. *Adv Mater* **18**, 165, 2006.
 96. Bettinger, C.J., Cyr, K.M., Matsumoto, A., Langer, R., Borenstein, J.T., and Kaplan, D.L. Silk fibroin microfluidic devices. *Adv Mater* **19**, 2847, 2007.
 97. Altman, G.H., Diaz, F., Jakuba, C., Calabro, T., Horan, R.L., Chen, J., Lu, H., Richmond, J., and Kaplan, D.L. Silk-based biomaterials. *Biomaterials* **24**, 401, 2003.
 98. Choi, N.W., Cabodi, M., Held, B., Glegghorn, J.P., Bonassar, L.J., and Stroock, A.D. Microfluidic scaffolds for tissue engineering. *Nat Mater* **6**, 908, 2007.
 99. Tang, M.D., Golden, A.P., and Tien, J. Fabrication of collagen gels that contain patterned, micrometer-scale cavities. *Adv Mater* **16**, 1345, 2004.
 100. Golden, A.P., and Tien, J. Fabrication of microfluidic hydrogels using molded gelatin as a sacrificial element. *Lab Chip* **7**, 720, 2007.
 101. Kelm, J.M., Djonov, V., Ittner, L.M., Fluri, D., Born, W., Hoerstrup, S.P., and Fussenegger, M. Design of custom-shaped vascularized tissues using microtissue spheroids as minimal building units. *Tissue Eng* **12**, 2151, 2006.

102. McGuigan, A.P., and Sefton, M.V. Vascularized organoid engineered by modular assembly enables blood perfusion. *Proc Natl Acad Sci USA* **103**, 11461, 2006.
103. Leung, B.M., and Sefton, M.V. A modular tissue engineering construct containing smooth muscle cells and endothelial cells. *Ann Biomed Eng* **35**, 2039, 2007.
104. McGuigan, A.P., and Sefton, M.V. The thrombogenicity of human umbilical vein endothelial cell seeded collagen modules. *Biomaterials* **29**, 2453, 2008.
105. Chrobak, K.M., Potter, D.R., and Tien, J. Formation of perfused, functional microvascular tubes *in vitro*. *Microvasc Res* **71**, 185, 2006.
106. Neumann, T., Nicholson, B.S., and Sanders, J.E. Tissue engineering of perfused microvessels. *Microvasc Res* **66**, 59, 2003.
107. Lovett, M., Cannizzaro, C., Daheron, L., Messmer, B., Vunjak-Novakovic, G., and Kaplan, D.L. Silk fibroin microtubes for blood vessel engineering. *Biomaterials* **28**, 5271, 2007.
108. Sekine, H., Shimizu, T., Yang, J., Kobayashi, E., and Okano, T. Pulsatile myocardial tubes fabricated with cell sheet engineering. *Circulation* **114**, I87, 2006.
109. Yang, J., Yamato, M., Shimizu, T., Sekine, H., Ohashi, K., Kanzaki, M., Ohki, T., Nishida, K., and Okano, T. Reconstruction of functional tissues with cell sheet engineering. *Biomaterials* **28**, 5033, 2007.
110. Shimizu, T., Sekine, H., Yang, J., Isoi, Y., Yamato, M., Kikuchi, A., Kobayashi, E., and Okano, T. Polysurgery of cell sheet grafts overcomes diffusion limits to produce thick, vascularized myocardial tissues. *FASEB J* **20**, 708, 2006.
111. Lokmic, Z., Stillaert, F., Morrison, W.A., Thompson, E.W., and Mitchell, G.M. An arteriovenous loop in a protected space generates a permanent, highly vascular, tissue-engineered construct. *FASEB J* **21**, 511, 2007.
112. Mian, R., Morrison, W.A., Hurley, J.V., Penington, A.J., Romeo, R., Tanaka, Y., and Knight, K.R. Formation of new tissue from an arteriovenous loop in the absence of added extracellular matrix. *Tissue Eng* **6**, 595, 2000.
113. Cassell, O.C.S., Morrison, W.A., Messina, A., Penington, A.J., Thompson, E.W., Stevens, G.W., Perera, J.M., Kleinman, H.K., Hurley, J.V., Romeo, R., and Knight, K.R. The influence of extracellular matrix on the generation of vascularized, engineered, transplantable tissue. *Annals of the New York Academy of Sciences*, **944**, 429, 2001.
114. Manasseri, B., Cuccia, G., Moimas, S., D'Alcontres, F.S., Polito, F., Bitto, A., Altavilla, D., Squadrito, F., Geuna, S., Pattarini, L., Zentilin, L., Collesi, C., Puligadda, U., Giacca, M., and Colonna, M.R. Microsurgical arteriovenous loops and biological templates: a novel *in vivo* chamber for tissue engineering. *Microsurgery* **27**, 623, 2007.
115. Morritt, A.N., Bortolotto, S.K., Dilley, R.J., Han, X., Kompa, A.R., McCombe, D., Wright, C.E., Itescu, S., Angus, J.A., and Morrison, W.A. Cardiac tissue engineering in an *in vivo* vascularized chamber. *Circulation* **115**, 353, 2007.
116. Kneser, U., Polykandriotis, E., Ohnolz, J., Heidner, K., Grabinger, L., Euler, S., Amann, K.U., Hess, A., Brune, K., Greil, P., Stürzl, M., and Horch, R.E. Engineering of vascularized transplantable bone tissues: induction of axial vascularization in an osteoconductive matrix using an arteriovenous loop. *Tissue Eng* **12**, 1721, 2006.
117. Bach, A.D., Arkudas, A., Tjiawi, J., Polykandriotis, E., Kneser, U., Horch, R.E., and Beier, J.P. A new approach to tissue engineering of vascularized skeletal muscle. *J Cell Mol Med* **10**, 716, 2006.
118. Beier, J.P., Horch, R.E., Arkudas, A., Polykandriotis, E., Bleiziffer, O., Adamek, E., Hess, A., and Kneser, U. *De novo* generation of axially vascularized tissue in a large animal model. *Microsurgery* **29**, 42, 2009.
119. Laschke, M.W., Harder, Y., Amon, M., Martin, I., Farhadi, J., Ring, A., Torio-Padron, N., Schramm, R., Rücker, M., Junker, D., Häufel, J.M., Carvalho, C., Heberer, M., Germann, G., Vollmar, B., and Menger, M.D. Angiogenesis in tissue engineering: breathing life into constructed tissue substitutes. *Tissue Eng* **12**, 2093, 2006.
120. Hellums, J.D., Nair, P.K., Huang, N.S., and Ohshima, N. Simulation of intraluminal gas transport processes in the microcirculation. *Ann Biomed Eng* **24**, 1, 1996.
121. Jain, R.K. Transport of molecules across tumor vasculature. *Cancer Metastasis Rev* **6**, 559, 1987.
122. Eggleton, C.D., Vadapalli, A., Roy, T.K., and Popel, A.S. Calculations of intracapillary oxygen tension distributions in muscle. *Math Biosci* **167**, 123, 2000.
123. Griffith, L.G., and Swartz, M.A. Capturing complex 3D tissue physiology *in vitro*. *Nat Rev Mol Cell Biol* **7**, 211, 2006.
124. Jain, R.K. Transport of molecules in the tumor interstitium: a review. *Cancer Res* **47**, 3039, 1987.
125. Davis, B.H., Schroeder, T., Yarmolenko, P.S., Guilak, F., Dewhirst, M.W., and Taylor, D.A. An *in vitro* system to evaluate the effects of Ischemia on survival of cells used for cell therapy. *Ann Biomed Eng* **35**, 1414, 2007.
126. Berkovitz, G.D., Fujimoto, M., Brown, T.R., Brodie, A.M., and Migeon, C.J. Aromatase activity in cultured human genital skin fibroblasts. *J Clin Endocrinol Metab* **59**, 665, 1984.
127. Radisic, M., Deen, W., Langer, R., and Vunjak-Novakovic, G. Mathematical model of oxygen distribution in engineered cardiac tissue with parallel channel array perfused with culture medium containing oxygen carriers. *Am J Physiol Heart Circ Physiol* **288**, H1278, 2005.
128. Truskey, G.A., Yuan, F., and Katz, D.F. *Transport Phenomena in Biological Systems*. Upper Saddle River, NJ: Pearson Prentice Hall, 2004.
129. Chary, S.R., and Jain, R.K. Direct measurement of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluorescence photobleaching. *Proc Natl Acad Sci USA* **86**, 5385, 1989.
130. Zhao, F., Pathi, P., Grayson, W., Xing, Q., Locke, B.R., and Ma, T. Effects of oxygen transport on 3-D human mesenchymal stem cell metabolic activity in perfusion and static cultures: experiments and mathematical model. *Biotechnol Prog* **21**, 1269, 2005.
131. Cochran, D.M., Fukumura, D., Ancukiewicz, M., Carmeliet, P., and Jain, R.K. Evolution of oxygen and glucose concentration profiles in a tissue-mimetic culture system of embryonic stem cells. *Ann Biomed Eng* **34**, 1247, 2006.
132. Kellner, K., Liebsch, G., Klimant, I., Wolfbeis, O.S., Blunk, T., Schulz, M.B., and Gopferich, A. Determination of oxygen gradients in engineered tissue using a fluorescent sensor. *Biotechnol Bioeng* **80**, 73, 2002.
133. Revsbech, N.P., and Ward, D.M. Oxygen microelectrode that is insensitive to medium chemical composition: use in an acid microbial mat dominated by cyanidium caldarium. *Appl Environ Microbiol* **45**, 755, 1983.
134. Malda, J., Rouwkema, J., Martens, D.E., Le Comte, E.P., Kooy, F.K., Tramper, J., van Blitterswijk, C.A., and Riesle, J.

- Oxygen gradients in tissue-engineered PEGT/PBT cartilaginous constructs: measurement and modeling. *Bio-technol Bioeng* **86**, 9, 2004.
135. Krihak, M.K., and Shahriari, M.R. Highly sensitive, all solid state fibre optic oxygen sensor based on the sol-gel coating technique. *Electron Lett* **32**, 240, 1996.
 136. Fink, T., Abildtrup, L., Fogd, K., Abdallah, B.M., Kassem, M., Ebbesen, P., and Zachar, V. Induction of adipocyte-like phenotype in human mesenchymal stem cells by hypoxia. *Stem Cells* **22**, 1346, 2004.
 137. Vanderkooi, J.M., Maniara, G., Green, T.J., and Wilson, D.F. An optical method for measurement of dioxygen concentration based upon quenching of phosphorescence. *J Biol Chem* **262**, 5476, 1987.
 138. Filho, I.P.T., and Intaglietta, M. Microvessel PO₂ measurements by phosphorescence decay method. *Am J Physiol Heart Circ Physiol* **265**, H1434, 1993.
 139. Guaccio, A., Borselli, C., Oliviero, O., and Netti, P.A. Oxygen consumption of chondrocytes in agarose and collagen gels: a comparative analysis. *Biomaterials* **29**, 1484, 2008.
 140. Vinogradov, S.A., Lo, L.W., Jenkins, W.T., Evans, S.M., Koch, C., and Wilson, D.F. Noninvasive imaging of the distribution in oxygen in tissue *in vivo* using near-infrared phosphors. *Biophys J* **70**, 1609, 1996.
 141. Lo, L.W., Koch, C.J., and Wilson, D.F. Calibration of oxygen-dependent quenching of the phosphorescence of Pd-meso-tetra (4-carboxyphenyl) porphine: a phosphor with general application for measuring oxygen concentration in biological systems. *Anal Biochem* **236**, 153, 1996.
 142. Wilson, D.F., Lee, W.M.F., Makonnen, S., Finikova, O., Apreleva, S., and Vinogradov, S.A. Oxygen pressures in the interstitial space and their relationship to those in the blood plasma in resting skeletal muscle. *J Appl Physiol* **101**, 1648, 2006.
 143. Helmlinger, G., Yuan, F., Dellian, M., and Jain, R.K. Interstitial pH and pO₂ gradients in solid tumors *in vivo*: high-resolution measurements reveal a lack of correlation. *Nat Med* **3**, 177, 1997.

Address correspondence to:

David L. Kaplan, Ph.D.

Department of Biomedical Engineering

Tufts University

4 Colby St.

Medford, MA 02155

E-mail: david.kaplan@tufts.edu

Received: February 6, 2009

Accepted: June 4, 2009

Online Publication Date: July 7, 2009